antirheumatic drug
<p>Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis</p>
... disease-modifying antirheumatic drug; CHEERS, the Consolidated Health Economic Evaluation Reporting Standards; CI, con fi dence intervals; combi, combi- nation therapy; csDMARD, conventional synthetic ...
10
Factors associated with the achievement of biological disease modifying antirheumatic drug free remission in rheumatoid arthritis: the ANSWER cohort study
... disease-modifying antirheumatic drug; BFR: bDMARD-free remission; CCP: Cyclic citrullinated peptide; CI: Confidence interval; csDMARD: Conventional synthetic DMARD; CZP: Certolizumab pegol; DAS28-CRP: ...
10
Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration
... TXNIP). Antirheumatic treatment with SAIDs showed complete and strong reversion of RA- related gene expression in human chondrocytes, whereas treatment with NSAIDs and the DMARD chloroquine phosphate ADORA2A: ...
14
Does the presence of magnetic resonance imaging detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease modifying antirheumatic drug free sustained remission: results of a longitudinal study
... Background: Although infrequent, some rheumatoid arthritis (RA) patients achieve disease-modifying antirheumatic drug (DMARD)-free sustained remission. The absence of RA-specific autoantibodies, such as ...
8
Early combination disease modifying antirheumatic drug therapy and tight disease control improve long term radiologic outcome in patients with early rheumatoid arthritis: the 11 year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
... From April 1993 to May 1995, 199 DMARD-naïve patients with recent-onset RA were admitted to this ran- domized study comparing the efficacy and tolerability of treatment with either a combination of DMARDs (start- ing ...
8
Slow-Acting Antirheumatic Drug Use in Systemic Onset Juvenile Chronic Arthritis
... This study shows that gold treatment is not useful in the systemic phase of the illness, as it has no effect on systemic features, very little effect on joint activity, rarely allows red[r] ...
7
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis
... modifying antirheumatic drug; EULAR: European League Against Rheumatism; HAQ: health assessment questionnaire; iCombo: initial combination therapy; iMono: initial monotherapy; MTX: methotrexate; non-PP: ...
9
Towards a conceptual framework demonstrating the effectiveness of audiovisual patient descriptions (patient video cases): a review of the current literature
... Table 3 Identification of health care settings in which educational patient video clips have been utilised Continued Ankylosing spondylitis antirheumatic drug trials: Effects of a standa[r] ...
16
Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?
... Abbreviations ACPA: anti-citrullinated peptide antibodies; ACR: American College of Rheumatolgy; CRP: C-reactive protein; DMARD: disease modifying antirheumatic drug; EA: early arthritis[r] ...
10
Comparative evaluation of the effects of treatment with tocilizumab and TNF α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients
... modifying antirheumatic drug (DMARD) or immu- nosuppressant were recommended for treatment with tocilizumab or TNF-α inhibitors by their attending physi- ...
10
Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis
... joints; DMARD: Disease-modifying antirheumatic drug; DSema7A: Heat-denatured Sema7A; ELISA: Enzyme-linked immunosorbent assay; FACS: Fluorescenceactivated cell-sorting; FAK: Focal adhesi[r] ...
12
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis
... modifying antirheumatic drug; DSM-IV: American Psychiatric Association ’ s Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; ESR: Erythrocyte sedimentation rate; HAQ-DI: Health Assessment ...
12
Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
... disease-modifying antirheumatic drug; esr, erythrocyte sedimentation rate; crP, c-reactive protein; DAs28, 28-joint Disease Activity score; hAQ, health assessment questionnaire; VAs global, visual analog ...
8
Ultrasound detected bone erosion is a relapse risk factor after discontinuation of biologic disease modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
... disease-modifying antirheumatic drug; CDAI: Clinical Disease Activity Index; cDMARD: Conventional disease- modifying antirheumatic drug; CRP: C-reactive protein; CZP: Certolizumab pegol; ...
8
The isotype repertoire of antibodies against novel UH RA peptides in rheumatoid arthritis
... Abbreviations ACPA, anticitrullinated protein antibodies; CCP, cyclic citrullinated peptide; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; FcR, Fc rec[r] ...
9
Upadacitinib improves patient reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease modifying antirheumatic drugs: results from SELECT NEXT
... disease-modifying antirheumatic drug; BP: Bodily pain; CI: Confidence interval; csDMARD: Conventional synthetic disease-modifying antirheumatic drug; CCP: Cyclic citrullinated peptide; CDAI: ...
11
Head to head comparison of aggressive conventional therapy and three biological treatments and comparison of two de escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open label, blinded assessor, phase 4 study
... modifying antirheumatic drug therapy; AE: Adverse event; ALAT: Alanine transaminase; ANA: Anti-nuclear antibody; ANOVA: Analysis of variance; ASAT: Aspartate transaminase; BL: Baseline; CDAI: Clinical ...
17
The value of the simplified RAMRIS 5 in early RA patients under methotrexate therapy using high field MRI
... Abbreviations ACR: American College of Rheumatology; CI: Confidence interval; CRP: Creactive protein; csDMARD: Conventional synthetic disease-modifying antirheumatic drug; DAS-28: Diseas[r] ...
8
Antirheumatic drugs and reproduction in women and men with chronic arthritis
... biological antirheumatic treatment during gestation as ...studied antirheumatic biological drugs, do not impair fertility in men, 32 33 and seem to be potential therapeutic agents for treating some types of ...
6
Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis
... Parents were shown the following question: “When making decisions about your child’s health, how con- cerned are you about the following issues related to pre- scription medications your child is taking?” and asked to ...
11